Although MCM6 protein expression was not associated with clinicopathologic features such as age, gender, Lauren subtype, tumor grade, tumor node metastasis (TNM) stage, and lymph node metastasis (Table S5), Kaplan-Meier survival analysis showed that patients with high-MCM6-expressing GC (43.6%, 115/264) survived for a significantly shortened time than those with low-MCM6-expressing tumors (P = 0.0077; Figure 2G). This evidence concerns the gene MCM6 and gastric cancer.